Literature DB >> 32369281

A Trial of Lopinavir-Ritonavir in Covid-19.

Piero Dalerba1, Bruce Levin1, John L Thompson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32369281     DOI： 10.1056/NEJMc2008043

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  13 in total

Review 1.  Flavonoids are promising safe therapy against COVID-19.

Authors:  Moza Mohamed Alzaabi; Rania Hamdy; Naglaa S Ashmawy; Alshaimaa M Hamoda; Fatemah Alkhayat; Neda Naser Khademi; Sara Mahmoud Abo Al Joud; Ali A El-Keblawy; Sameh S M Soliman
Journal:  Phytochem Rev       Date:  2021-05-22       Impact factor: 7.741

2.  A scheme for inferring viral-host associations based on codon usage patterns identifies the most affected signaling pathways during COVID-19.

Authors:  Jayanta Kumar Das; Subhadip Chakraborty; Swarup Roy
Journal:  J Biomed Inform       Date:  2021-05-07       Impact factor: 8.000

Review 3.  While We Wait for a Vaccine Against SARS-CoV-2, Why Not Think About Available Drugs?

Authors:  Francisco J Barrantes
Journal:  Front Physiol       Date:  2020-07-03       Impact factor: 4.566

4.  A severe COVID-19 despite ongoing treatment with Lopinavir-Ritonavir.

Authors:  H Joumaa; L Regard; N Carlier; G Chassagnon; E Alabadan; E Canouï; A L'honneur; F Rozenberg; P-R Burgel; N Roche
Journal:  Respir Med Res       Date:  2020-07-15

5.  Comparative effectiveness and safety of antiviral agents for patients with COVID-19: Protocol for a systematic review and individual-patient data network meta-analysis.

Authors:  Yulong Cao; Jiao Shan; Zhizhong Gong; Jiqiu Kuang; Yan Gao
Journal:  PLoS One       Date:  2020-11-09       Impact factor: 3.240

Review 6.  A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs.

Authors:  Po-Lin Chen; Nan-Yao Lee; Cong-Tat Cia; Wen-Chien Ko; Po-Ren Hsueh
Journal:  Front Pharmacol       Date:  2020-11-17       Impact factor: 5.810

7.  COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm.

Authors:  Cirino Botta; Alessia Indrieri; Eugenio Garofalo; Flavia Biamonte; Andrea Bruni; Pino Pasqua; Francesco Cesario; Francesco Saverio Costanzo; Federico Longhini; Francesco Mendicino
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 6.244

8.  SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target.

Authors:  Bingqing Xia; Xurui Shen; Yang He; Xiaoyan Pan; Feng-Liang Liu; Yi Wang; Feipu Yang; Sui Fang; Yan Wu; Zilei Duan; Xiaoli Zuo; Zhuqing Xie; Xiangrui Jiang; Ling Xu; Hao Chi; Shuangqu Li; Qian Meng; Hu Zhou; Yubo Zhou; Xi Cheng; Xiaoming Xin; Lin Jin; Hai-Lin Zhang; Dan-Dan Yu; Ming-Hua Li; Xiao-Li Feng; Jiekai Chen; Hualiang Jiang; Gengfu Xiao; Yong-Tang Zheng; Lei-Ke Zhang; Jingshan Shen; Jia Li; Zhaobing Gao
Journal:  Cell Res       Date:  2021-06-10       Impact factor: 46.297

9.  Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients.

Authors:  Jean Claude Alvarez; Pierre Moine; Benjamin Davido; Isabelle Etting; Djillali Annane; Islam Amine Larabi; Nicolas Simon
Journal:  Eur J Clin Pharmacol       Date:  2020-10-13       Impact factor: 2.953

10.  Recent progress of antiviral therapy for coronavirus disease 2019.

Authors:  Mengmeng Zhao; Jishou Zhang; Hanli Li; Zhen Luo; Jing Ye; Yao Xu; Zhen Wang; Di Ye; Jianfang Liu; Dan Li; Menglong Wang; Jun Wan
Journal:  Eur J Pharmacol       Date:  2020-10-24       Impact factor: 4.432
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.